Orforglipron is emerging as a groundbreaking medication in the battle against diabetes and obesity, particularly as it represents Eli Lilly's first foray into the realm of oral GLP-1 treatments.This innovative diabetes drug has shown remarkable potential in clinical trials, not only lowering A1C levels but also promoting significant weight loss among participants.